This article summarized the latest R&D progress of nitrendipine, the Mechanism of Action for nitrendipine, and the drug target R&D trends for nitrendipine.
Recently, UCB announced that the FDA has approved Bimzelx(bimekizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic treatment or phototherapy.
This article summarized the latest R&D progress of osimertinib mesylate, the Mechanism of Action for osimertinib mesylate, and the drug target R&D trends for osimertinib mesylate.
This article summarized the latest R&D progress of metergoline, the Mechanism of Action for metergoline, and the drug target R&D trends for metergoline.
Angany Inc.. has revealed that it has obtained approval from MHRA to carry out the initial clinical trial of its vaccine candidate ANG-101 aimed at combating allergies in humans to cats.
This article summarized the latest R&D progress of lusutrombopag, the Mechanism of Action for lusutrombopag, and the drug target R&D trends for lusutrombopag.
In the wake of the receding tide of COVID-19 oral medication and vaccines, Pfizer seems to have returned to an awkward predicament where all potential growth points have fallen flat.
This article summarized the latest R&D progress of methscopolamine bromide, the Mechanism of Action for methscopolamine bromide, and the drug target R&D trends for methscopolamine bromide.